D C Klonoff
Affiliation: University of California
- Inhaled insulinD C Klonoff
University of California at San Francisco, Burlingame, California, USA
Diabetes Technol Ther 1:307-13. 1999..Inhaled insulin will become established if ongoing studies continue to demonstrate this technology to be safe and effective...
- A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosagesDavid C Klonoff
Dorothy L. and James E. Frank Diabetes Research Institute, Mills-Peninsula Health Services, San Mateo, California 94401, USA
Diabetes Technol Ther 5:453-4. 2003
- An economic analysis of interventions for diabetesD C Klonoff
Department of Medicine, University of California at San Francisco, USA
Diabetes Care 23:390-404. 2000..Widely practiced interventions for patients with diabetes can be clearly cost-saving and clearly cost-effective. These practices are attractive from both a medical and an economic perspective...
- A review of continuous glucose monitoring technologyDavid C Klonoff
University of California San Francisco, San Francisco, California, USA
Diabetes Technol Ther 7:770-5. 2005
- Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin deliveryDavid C Klonoff
Mills Peninsula Diabetes Research Institute, San Mateo, California 94401, USA
Pediatr Endocrinol Rev 1:94-100. 2003..new routes of insulin administration, including inhaled, oral, buccal, nasal, and transdermal drug delivery systems. These new technologies will facilitate proper treatment of type 1 diabetes and improve the lives of affected patients...
- Continuous glucose monitoring: roadmap for 21st century diabetes therapyDavid C Klonoff
Mills-Peninsula Health Services Diabetes Research Institute, 100 S. San Mateo Dr, Rm. 3124, San Mateo, CA 94401, USA
Diabetes Care 28:1231-9. 2005
- Current, emerging, and future trends in metabolic monitoringDavid C Klonoff
Diabetes Technol Ther 4:583-8. 2002
- The First Annual Diabetes Technology Meeting--a new forum for accelerating the development of technology to fight diabetesDavid C Klonoff
Diabetes Technol Ther 4:201-2. 2002
- Subcutaneous continuous glucose monitoring in severe burn patientsDavid C Klonoff
Crit Care Med 35:1445; author reply 1445-6. 2007
- Time synching or time sinking?Daniel J Crowe
Diabetes Technol Ther 7:663-4. 2005
- Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialsJohn B Buse
Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
Clin Ther 29:139-53. 2007..Some patients were followed up in open-label extensions to provide 'real-world' exenatide clinical experience...
- An adaptive drug infusion systemMeghan Simmons
TheraFuse, Inc, Carlsbad, California 92008, USA
Diabetes Technol Ther 6:607-20. 2004..CONCLUSIONS: The performance of the prototypes demonstrates that real-time compensation of flow variables provides significant performance improvements in therapeutic infusion...
- The need for separate performance goals for glucose sensors in the hypoglycemic, normoglycemic, and hyperglycemic rangesDavid C Klonoff
Diabetes Care 27:834-6. 2004
- Microdialysis of interstitial fluid for continuous glucose measurementDavid C Klonoff
Diabetes Technol Ther 5:539-43. 2003
- The link between diabetes, military metabolic monitoring, and NASADavid C Klonoff
Diabetes Technol Ther 5:351-3. 2003
- Diabetes and telemedicine: is the technology sound, effective, cost-effective, and practical?David C Klonoff
Diabetes Care 26:1626-8. 2003
- European trends in diabetes technology--continuous glucose measurements and computerized information-processing toolsDavid C Klonoff
Diabetes Technol Ther 4:763-4. 2002
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsDavid C Klonoff
Diabetes Research Institute, Mills Peninsula Health Services, San Mateo, CA, USA
Curr Med Res Opin 24:275-86. 2008..The objective of this study was to evaluate the effects of > or = 3 years exenatide therapy on glycemic control, body weight, cardiometabolic markers, and safety...